Cargando…
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
BACKGROUND/PURPOSE: Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early...
Autores principales: | Pan, Calvin Q., Chang, Ting-Tsung, Bae, Si Hyun, Brunetto, Maurizia, Seto, Wai-Kay, Coffin, Carla S., Tan, Susanna K., Mo, Shuyuan, Flaherty, John F., Gaggar, Anuj, Nguyen, Mindie H., Çelen, Mustafa Kemal, Thompson, Alexander, Gane, Edward J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118264/ https://www.ncbi.nlm.nih.gov/pubmed/33984038 http://dx.doi.org/10.1371/journal.pone.0251552 |
Ejemplares similares
-
3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021) -
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023) -
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil
Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020) -
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016) -
Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)